Navigation Links
First noninvasive technique to accurately predict mutations in human brain tumors
Date:4/20/2009

DENVER Donald O'Rourke, MD, Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine and colleagues, were able to accurately predict the specific genetic mutation that caused brain cancer in a group of patients studied using magnetic resonance imaging (MRI). The researchers presented their findings this week at the American Association for Cancer Research 100th Annual Meeting 2009.

"The field of cancer research has evolved to the point where the identification of the mutations that cause tumors has changed how we treat patients in a number of cancers," says O'Rourke. "Potentially, we believe we have a method that uses MRI to identify a tumor mutation. Historically tumor mutations have been identified in only one way: take the tissue out and examine it using one of two laboratory tests to see if the mutation is present. In this study we've done this identification noninvasively. To my knowledge this is the first demonstration that an MRI, or any imaging technique, can accurately predict the type of mutation of a human tumor."

A particular MRI technique, called relative cerebral blood volume that measures blood flow to the tumor, very highly correlates with the presence of an important mutation in glioblastoma, a type of brain cancer. The mutation occurs in the epidermal growth factor receptor, EGFR, a well known cancer-related protein that helps tumors form their necessary blood vessels. EGFRvIII, the specific mutation the Penn group studied, is the hallmark of a more aggressive form of glioblastoma.

The research team compared MRI readings to tumor tissue samples from 97 glioblastoma patients. They found that patients with higher relative cerebral blood volume as measured by MRI correlates with the EGFRvIII mutation compared to those who did not have the mutation.

Glioblastoma is a variable disease, and clinicians need help to distinguish one form from another. "All of cancer research is evolving to a point where mutations can facilitate care, so a more accurate diagnosis and treatment course can be better planned by identifying the mutational status of the tumor," says O'Rourke.

EGFRvIII is an area of intense interest in the field of cancer, being associated with more aggressive cancers. Having a noninvasive way to identity patients with the EGFRvIII mutation could allow physicians to enroll these patients into trials using drugs that specifically target this mutation. Penn is part of a multicenter trial that is doing just that.

Another implication of having a noninvasive method to track a specific patient group is for following treatment response. "Currently we identify a tumor mutation by removing a tumor, and then we select a particular treatment and evaluate the response with an MRI to see if the tumor is stable or smaller," explains O'Rourke. "With this new method we'll be able to show whether a surrogate of the mutation is changing. EGFRvIII correlates with the elevated blood flow to the tumor and if we put a patient on an effective anti-tumor strategy, that blood flow should reduce. We'd be getting a more biological readout to therapy."

Ongoing work focuses on using advanced MRI to characterize additional mutations in glioblastoma tumors.


'/>"/>

Contact: Karen Kreeger
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Sitting at the Virtual Poker Table: Results From First Ever Epidemiological Study of Actual Internet Poker Gaming Behavior, in Press
2. IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results
3. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
4. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
5. First Annual World Meningitis Day Gaining National Support
6. Lilly Reports Strong First-Quarter 2009 Results
7. First Woman President of the AVMA to Speak at Ross University School of Veterinary Medicine's 2009 Graduation
8. U.S. Venture Investment Lowest in 11 Years, Down 50% to $3.9 Billion in First Quarter
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
10. Pennsylvania Governors Food Safety Council to Hold First Meeting on April 22
11. Caliper Life Sciences First Quarter 2009 Financial Results Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March ... the US Special Operations Command’s Patriot Award. The award was presented by the ... Force Dagger Foundation for its significant and enduring support to the command. ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony ... the creation of published author Bonetta Rose, a wife, mother and grandmother committed to ... by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the life ...
(Date:3/23/2017)... ... ... Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The Trainer” is ... an enthusiasm for action and adventure stories. , Published by Christian Faith ... at the thirty-three notches that lined the edges of the wooden grip plates of ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD announces that AB Laboratories ... in its licensed production facility under the Access to ... Hamilton, Ontario . The ... in October 2016, is currently operating at half capacity, ...
(Date:3/23/2017)... 23, 2017 Piramal Pharma ... anuncia el nombramiento de Stuart E. Needleman ... de servicios integrados completa para su base de ... clave en el crecimiento y ejecución de las ... de impulsar todas las actividades de desarrollo empresarial ...
(Date:3/23/2017)... TEL AVIV, Israel, March 23, 2017  Galmed ... or the "Company"), a clinical-stage biopharmaceutical company focused ... for the treatment of nonalcoholic steatohepatitis, or NASH, ... for the three and twelve months ended December 31, ... recently completed pre-clinical studies demonstrating Aramchol™,s potential direct ...
Breaking Medicine Technology: